Protara Therapeutics (TARA) KOL event summary

Introduction and agenda

• Provided an overview of the lymphatic malformations (LMs) program, recent FDA interactions, and plans for a BLA submission for TARA-002 in 2H 2027.

• Focused on TARA-002 as a targeted, minimally invasive therapy for macrocystic and mixed LMs, highlighting unmet needs, clinical progress, and pivotal STARBORN-1 trial updates.

• The agenda included presentations from clinical investigators, R&D, commercial, and finance leaders, case studies, market overview, and a Q&A session.

KOL background and credentials

• Dr. Naiem Nassiri: Board-certified vascular/endovascular surgeon, founder of a leading vascular malformations center, treats 400+ cases annually, former Yale faculty.

• Dr. Jesse G.A. Jones: Board-certified interventional neuroradiologist, associate professor at UAB, manages 50+ vascular anomaly patients annually.

• Presenters included Jacqueline Zummo, PhD.

Market insights and analysis

• Estimated 1,500 new LM diagnoses annually in the US, with up to 80,000 prevalent cases; 20,000 have macrocystic or mixed disease seeking treatment.

• Macrocystic and mixed cystic LMs represent ~79% of cases, with a total addressable market for TARA-002 projected at over $1 billion.

• LMs are rare, congenital malformations with significant morbidity and no FDA-approved therapies; current treatments lack approval and have high recurrence and variable outcomes.

• Most patients are diagnosed in the community and referred to vascular anomaly centers; top 100 accounts treat ~80% of LM patients, supporting a focused commercial launch.